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A B ST R AC T 
 
 
Personalized treatment in oncology is the most innovative method of 
care. The best method to establish personalized treatment is by genetic 
characterization of the malignant cell.  
Theoretically, the more detailed the characterization, the more effective 
the choice of treatment becomes. Currently, there are fast and relatively 
low-cost options that allow such genetic characterization. However, test 
results sometimes do not detect targetable alterations and, even if they 
do detect, the use of the treatment-alteration combination does not 
always generate a satisfactory oncological response.  
The present paper aims to answer two questions. First, how targetable 
can the most common gene alterations in colorectal cancer be. Second, 
whether it makes sense to use broad molecular testing as a standard in 
all metastatic patients.   
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Introduction  
In order to personalize oncological systemic therapy, it 
is essential to characterize the tumor cell as good as 
possible. In order to do so, broad molecular testing is often 
required, including next-generation sequencing for a large 
panel of gene alterations. Following the information 
obtained, it is possible to decide upon the optimal treatment 
to target the mutations found. Although it sounds ideal, this 
process is also full of obstacles, such as the accessibility of 
the tests, the availability of the drugs that correspond to 
these alterations, the costs, the lack of expertise of the 
doctors who should interpret the results. Last but not least, 
the level of evidence for alteration-treatment associations 
is different for each cancer site.  
The present review aims at answering two questions: 
how targetable can the most common gene alterations in 
colorectal cancer be and whether it makes sense to use 
broad molecular testing as a standard procedure in  
all metastatic patients. 
In order to get the answers, an inquiry was made in the 
PubMed and Scopus databases using keywords such as: 
genomic alteration, next-generation sequencing and 
colorectal cancer.  
Only the articles published between 2015 and 2020 
were included. In addition, some landmark trials that had 
been published before this time were also taken into 
consideration. 
A number of 218 articles were found (both original 
articles and systematic literature reviews). Out of these, 36 
have been selected for this paper. Their selection was made 
using the PICO criteria. 
The most noteworthy alterations for targeting 
metastatic colorectal cancer are KRAS/ NRAS, BRAF, 
NTRK1, ERBB2, PIK3CA, ATM, MET, AKT1, RET and 
ALK. 
The case of the patients with high tumor mutational 
burden (TMB) and microsatellite instability should also be 
considered, as they have been shown to be of particular 
importance in colorectal cancer [1]. 
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Several data found in the literature will be detailed in 
this review, which will conclude with discussions and 
interpretations related to the level of evidence for targeting 
each of the factors presented. 
Discussion 
RAS 
The genetic evolution of colorectal cancer involves 
tumor suppressor genes, mismatch repair genes, or 
epigenetic processes such as the hypomethylation or the 
hypermethylation of the DNA. They participate in 
tumorigenesis through the involvement in the stages of the 
cell cycle, but also through the direct clinical consequences 
of mutations [2]. 
The most important oncogene involved in the onset and 
development of colorectal cancer is RAS (Rat Sarcoma). 
The RAS oncogene has three sub-variants with 
relevance in colorectal cancer: HRAS, KRAS and NRAS. 
All of them can lead to normal cell transformation, but 
KRAS is the most often involved in carcinogenesis. RAS 
oncogenes encode proteins involved in the transmission of 
multiple extracellular growth signals to the nucleus. They 
ensure the transition from the inactive form related to GDP 
(guanosine diphosphate) to the active form that implies 
GTP (guanosine triphosphate). In the case of the above-
mentioned mutations, the GTP- bound active form is 
maintained in this continuous stage, stimulating cell 
division and growth [3-5]. 
These mutations are also involved in later processes 
involving tumor invasion and metastasis. RAS mutations 
are more common in proximal colon cancers [6,7]. 
The detection of RAS mutations in colorectal cancer is 
clinically important from at least two points of view: 
therapeutically and as a method of excluding patients for 
targeted therapy [8]. 
The involvement of the farnesyl transferase enzyme in 
the continuous activation of growth and division pathways 
by RAS is a scientific certainty. By inhibiting this enzyme, 
it is assumed that the effect of the KRAS mutation would 
be slowed down or stopped, thus this is currently the most 
interesting therapeutic target in these patients [9,10]. 
The presence of RAS mutations in colorectal cancer 
patients is associated with a lack of response to epidermal 
growth factor receptor (EGFR) inhibitors such as 
cetuximab or panitumumab. Therefore, testing metastatic 
patients for these mutations is essential for the decision on 
the treatment, which is currently standard [11,12]. 
B-RAF 
There are two subtypes of B-RAF mutations, 
depending on the different gene expression and molecular 
outcome: BM1 and BM2. In the case of the first, there is 
an activation of the KRAS / AKT pathway that translates 
into mesenchymal-epithelial transition and immune 
response, while the second involves abnormalities in the 
cell cycle and the immune checkpoint [13,14]. 
It is known that patients with B-RAF mutations have a 
worse prognosis than the wild-type ones (the wild-type 
ones have a double or even triple survival rate) [15,16]. 
However, the BM1 subtype of the B-RAF mutation is 
linked to the worst outcome. These remarks also explain 
the different responses to the treatment of these subtypes 
of patients [14]. 
The B-RAF mutation is less targeted in colorectal 
cancer than previously expected. The use of B-RAF 
inhibitors alone in metastatic colorectal cancer resulted in 
a 5% response rate [17-19]. 
From a molecular point of view, this reduced response 
is explained through the activation of the pathway 
involving EGFR with B-RAF blockade in this localization. 
In melanoma, for example, this does not happen because 
these cells have poorly expressed EGFR [20]. 
For this reason, the most widely used therapeutic option 
in patients with metastatic colorectal cancer is the 
combination of an EGFR inhibitor (cetuximab or 
panitumumab) and a B-RAF inhibitor (vemurafenib / 
dabrafenib / encorafenib) [21-24]. 
MSI 
Microsatellite instability (MSI) is a genetic 
predisposition to mutations that results from impaired 
DNA mismatch repair (MMR). Tumors with high 
microsatellite instability and DNA mismatch repair (MSI-
H/dMMR) are expressing higher numbers of neo-antigens 
which increase T-cell activation. Therefore, testing for 
mismatch repair deficiency (MMR-D)/MSI provides a 
predictive response to immune checkpoint inhibitors, but it 
is also a prognostic marker for fluorouracil chemotherapy 
response. 
Even though MSI detection was initially performed for 
the screening of Lynch syndrome, this molecular signature 
is found across a broad range of tumor types, and screening 
for microsatellite instability must become standard 
practice. 
Consequently, the international guidelines (ESMO- 
European Society for Medical Oncology and NCCN-The 
National Comprehensive Cancer Network) recommend 
MSI/ MMR testing for all the patients with colorectal 
cancer and uterine endometrioid carcinoma [25,26]. 
Traditionally, there are 2 methods of assessment of MSI 
/MMR deficient status: MSI analysis can be directly 
performed using the five microsatellite loci through 
polymerase chain reaction (PCR), and 
immunohistochemistry (IHC) is indirectly used to 
determine the loss of MMR gene expression (MLH1, 
MSH2, PMS2 or MSH6). 
Nowadays, emerging techniques have improved the 
detection of MSI. Next-Generation Sequencing (NGS) is a 
novel genetic diagnostic approach for tumor profiling for 
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microsatellite instability. NGS can scan countless 
microsatellites, or other targetable alterations suitable for 
the treatment, which allows a more thorough assessment. 
Other cancer sites can be tested as well [27,28]. 
Middha et al., developed a computational software 
program that combines NGS with biostatistics to address 
MSI in tumor tissue sampling, without the need for 
additional biological testing. MSI sensor is a 
computational tool that reports the percentage of unstable 
microsatellites as a score. An MSI high tumor is defined by 
an MSI sensor score higher than 10. This study 
predominantly included colorectal and endometrial cancers 
and found a high concordance between the traditional 
methods (PCR, IHC) and NGS (99.4%). However, NGS 
seemed slightly more sensitive than PCR and it had the 
potential of identifying the MSI missed through current 
laborious and time-consuming methods [29]. 
As mentioned above, KRAS/ NRAS mutation status or 
NGS tests should be performed in patients with MSS 
(microsatellite stable) colorectal tumors. Patients with 
MSI-H and MLH1 deficient colorectal cancers are at a high 
risk of developing Lynch syndrome and should undergo 
testing for the hypermethylation status of MLH1 
(MLH1ph). 
What is the relationship between MSI-H, MLH1 
deficient, BRAF /RAS wild type colorectal cancers and the 
presence of kinase fusions?  
Approximately 15% of advanced MSI-H/ MMR-D, 
BRAF /RAS wild-type colorectal cancers harbor kinase 
fusions. These kinase fusions are strongly associated with 
sporadic MLH1ph than with Lynch syndrome. Therefore, 
this subset of advanced colorectal tumors may benefit from 
targeting kinase fusions [30]. 
NTRK 
It is of interest to determine tumors that harbor NTRK 
fusions in colorectal cancer. NTRK fusion is frequently 
identified in rare cancer types and there are many strategies 
to target these oncogenic drivers through targeted kinase 
inhibitors. 
The European Society for Medical Oncology 
Translational Research and Precision Medicine Working 
Group reviewed the testing methods currently available for 
NTRK1/2/3 gene fusions. 
The methods of choice for the NTRK1/2/3 fusion gene 
include real-time PCR (RT-PCR), FISH (fluorescence in 
situ hybridization), IHC (immunohistochemistry), and 
NGS technology for DNA and RNA sequencing. 
There are limitations and strengths of each method. 
IHC is a time and tissue-efficient screening with lower 
costs for NTRK fusions especially in a population with a 
lower prevalence of molecular alterations. Some 
advantages of NGS sequencers are the high sensitivity and 
specificity in detecting a large number of mutations in a 
single assay, the RNA-based NGS methods being preferred 
for the detection of NTRK fusions [31,32]. 
Oncologists have a different attitude toward genomic 
testing, which may vary according to the types of 
assessment and their own experience. 
Recent data from the National Survey of Precision 
Medicine in Cancer Treatment revealed how confident 
oncologists are in using genomic medicine in clinical 
practice. To guide patient care, doctors are highly (60.1%) 
confident using next-generation sequencing (NGS) or gene 
expression (GE) tests. They are more confident when using 
a single gene testing approach than an entire genome 
sequencing.  
The oncologists' confidence is mostly influenced by the 
number of patients, the testing platform available and 
practice infrastructure. Moreover, doctors’ training and 
instruction are very important; continuous education can 
help keep their interest in medical advances [33]. 
Is genomic testing routine care?  
A French study tried to answer this question. In the 
ProfiLER trial, 2,579 metastatic and previously treated 
subjects (both adult and pediatric ones) underwent Next 
Generation Sequencing molecular profiling of 59 or 69 
cancer-related genes and whole-genome comparative 
genomic hybridization.  The goals of this study were to 
explain the nature and prevalence of specific alterations in 
the genetic material, and to assess the molecular profiling 
for precision cancer therapies.  
The results showed that the most common mutations 
were in the genes KRAS, CCND1, CDKN2A, PIKC3A. A 
molecular tumor board recommended targeted treatments 
in 27% of the patients, but unfortunately, only 6% received 
the recommended therapies.  
As a consequence, this study failed to prove its 
hypotheses, and genomic testing should not be used as 
routine screening care to select appropriate targeted 
therapies [34]. 
How can we stratify multigene testing in metastatic 
colorectal cancer? 
For the understanding of the targetability of gene 
alterations in colorectal cancer, we must first detail the 
ESCAT ((ESMO) European Society for Medical Oncology 
Scale for Clinical Actionability of Molecular Targets) 
classification. ESCAT I level means that the combination 
of gene alteration-drug has been validated in a clinical trial 
important enough for this to be the standard of care. 
ESCAT level II assumes that this combination is effective 
in phase II or I trial or in retrospective analyses. The 
alterations with ESCAT III evidence level are those with 
proven efficiency for other locations, but not for the one of 
interest. The data supporting alterations with ESCAT IV 
come from preclinical studies. This classification was 
validated by a panel of oncology experts with experience 
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in genetics and then validated by two other experts from 
outside the working group [1,35]. 
Thus, the gene alterations described above are 
classified as follows: KRAS has a prevalence of 44% and 
in its case, ESCAT classification is not possible, B-RAF 
with a prevalence of 8.5% and ESCAT I, MSI-H 4-5% and 
ESCAT I, NTRK fusion 0.5% and ESCAT I, ERBB2 
amplification 2% and ESCAT II, PIK3CA mutation 17% 
and ESCAT III, ATM 5% and ESCAT III, MET 1.7% and 
ESCAT III, RET and ALK fusions with a prevalence of 
0.3% and 0.2% and ESCAT III [36-42]. 
All in all, after stratifying the data, the ESMO 
recommendations are that multigene NGS tumor should 
remain an alternative to PCR (polymerase chain reaction) 
with the purpose of determining the above alterations if it 
does not involve additional costs [1]. 
Conclusions 
The use of NGS multigene makes sense in colorectal 
cancer as long as cost-effectiveness is maintained. 
Excluding the financial effect, these tests are a particularly 
important step in refining cancer research and accelerating 
the development of oncology drugs. To choose a large 
panel of genes is an option in non-targetable cancer sites 
with the hope that we will find those rare responders. If the 
treating oncologist decides to proceed this way, he must 
always inform them about the limited possibility of finding 
a corresponding treatment.  
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